Literature DB >> 10195870

Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.

I Sasagawa1, Y Kubota, T Nakada, H Suzuki, J Hirano, O Sugano, H Kato, A Imamura, K Mastushita, Y Onmura, M Saito, M Adachi.   

Abstract

Serum concentrations of luteinizing hormone (LH), testosterone, prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) were measured in 16 patients with advanced prostatic cancer before and after treatment with luteinizing hormone-releasing hormone (LHRH) analogue. An initial rise of serum LH and testosterone levels was observed on day 2 of the treatment. Subsequently, serum concentrations of PAP and PSA showed a transient increase on day 5 of the treatment. This indicates that LHRH analogues had better be given in combination with antiandrogens in patients with metastatic carcinoma of the prostate.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10195870     DOI： 10.1007/bf02564863

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  7 in total

1.  Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome.

Authors:  M Koutsilieris; N Faure; G Tolis; B Laroche; G Robert; C F Ackman
Journal:  Urology       Date:  1986-03       Impact factor: 2.649

2.  Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.

Authors:  J Waxman; A Man; W F Hendry; H N Whitfield; G M Besser; R C Tiptaft; A M Paris; R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-16

3.  Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.

Authors:  H Schulze; T Senge
Journal:  J Urol       Date:  1990-10       Impact factor: 7.450

4.  A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.

Authors:  H Winfield; J Trachtenberg
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

5.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

6.  The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man.

Authors:  D Heber; S Bhasin; B Steiner; R S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  1984-06       Impact factor: 5.958

7.  Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.

Authors:  N Faure; F Labrie; A Lemay; A Bélanger; Y Gourdeau; B Laroche; G Robert
Journal:  Fertil Steril       Date:  1982-03       Impact factor: 7.329
  7 in total
  4 in total

1.  Evaluation of degarelix in the management of prostate cancer.

Authors:  Hendrik Van Poppel
Journal:  Cancer Manag Res       Date:  2010-01-25       Impact factor: 3.989

Review 2.  Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.

Authors:  H Payne; M Mason
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

Review 3.  Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.

Authors:  Hiroaki Iwamoto; Kouji Izumi; Tomoyuki Makino; Atsushi Mizokami
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

4.  Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.

Authors:  Nicola J Nasser
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.